LY3509754 + midazolam

This is a **combination of LY3509754 and midazolam**, used in a clinical pharmacology context to evaluate drug-drug interaction, safety, tolerability, and pharmacokinetics. **LY3509754** is an orally bioavailable small-molecule inhibitor of **interleukin-17A (IL-17A)**, developed by Eli Lilly for the treatment of autoimmune diseases such as psoriasis. Its mechanism involves potent inhibition of IL-17A-mediated pro-inflammatory signaling. **Midazolam** is a well-characterized benzodiazepine used here as a sensitive probe/drug–drug interaction substrate of CYP3A enzymes, often included in DDI studies to test whether the investigational drug alters CYP3A metabolism. The combination does not represent a co-developed therapy but is specific to early-phase clinical studies evaluating pharmacokinetic interactions. - LY3509754: Oral small molecule IL-17A inhibitor (Eli Lilly) in development for autoimmune conditions, notably psoriasis. - Midazolam: Established benzodiazepine, CYP3A substrate, commonly used in clinical pharmacology for DDI evaluation.